Abstract
IBD includes two classic entities, Crohn's disease and ulcerative colitis, and a third undetermined form (IBD-U), characterized by a chronic relapsing course resulting in a high rate of morbidity and impaired quality of life. Children with IBD are vulnerable in terms of growth failure, malnutrition and emotional effects. The aims of therapy have now transitioned from symptomatic control to the achievement of mucosal healing and deep remission. This type of therapy has been made possible by the advent of disease-modifying drugs, such as biologic agents, which are capable of interrupting the inflammatory cascade underlying IBD. Biologic agents are generally administered in patients who are refractory to conventional therapies. However, there is growing support that such agents could be used in the initial phases of the disease, typically in paediatric patients, to interrupt and cease the inflammatory process. Until several years ago, most therapeutic programmes in paediatric patients with IBD were borrowed from adult trials, whereas paediatric studies were often retrospective and uncontrolled. However, guidelines on therapeutic management of paediatric IBD and controlled, prospective, randomized trials including children with IBD have now been published. Here, the current knowledge concerning treatment options for children with IBD are reported. We also highlight the effectiveness and safety of new therapeutic advances in these paediatric patients.
Key Points
-
Paediatric IBD often presents with a more severe phenotype and course than the adult-onset disease
-
Current therapeutic goals for paediatric IBD have evolved from symptomatic control towards the achievement of mucosal healing and deep remission
-
Advances in our understanding of the immunobiology of IBD have led to the discovery of biologic agents; using biologic agents as disease-modifying drugs in early IBD might induce disease stabilization and limit its progression
-
The aggressive nature and the evolution of IBD in childhood and its consequent metabolic effects make biologic agents an attractive option for many paediatric patients with IBD
-
Widely agreed data indicate that biologic agents in paediatric IBD facilitate mucosal healing and improve growth and quality of life by achieving steroid-sparing remission
-
Improved understanding of the mechanisms of paediatric IBD will lead to a recognition of which patients might most benefit from early use of biologic agents
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abraham, B. P., Mehta, S. & El-Serag, H. B. Natural history of pediatric-onset inflammatory bowel disease: a systematic review. J. Clin. Gastroenterol. 46, 581–589 (2012).
Benchimol, E. I. et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm. Bowel Dis. 17, 423–439 (2011).
Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46–54 (2012).
Malaty, H. M., Fan, X., Opekun, A. R., Thibodeaux, C. & Ferry, G. D. Rising incidence of inflammatory bowel disease among children: a 12-year study. J. Pediatr. Gastroenterol. Nutr. 50, 27–31 (2010).
Griffiths, A. M. Specificities of inflammatory bowel disease in childhood. Best Pract. Res. Clin. Gastroenterol. 18, 509–523 (2004).
Van Limbergen, J. et al. Definition of phenotypic characteristics of childhood onset inflammatory bowel disease. Gastroenterology 135, 1114–1122 (2008).
Vernier–Massouille, G. et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 135, 1106–1113 (2008).
Gower-Rousseau, C. et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am. J. Gastroenterol. 104, 2080–2088 (2009).
Savoye, G. et al. Clinical predictors at diagnosis of disabling pediatric Crohn's disease. Inflamm. Bowel Dis. 18, 2072–2078 (2012).
Levine, A. et al. Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS registry. Inflamm. Bowel Dis. 19, 370–377 (2013).
De Cruz, P., Kamm, M. A., Prideaux, L., Allen, P. B. & Moore, G. Mucosal healing in Crohn's disease: a systematic review. Inflamm. Bowel Dis. 19, 429–444 (2013).
Osterman, M. T. Mucosal healing in inflammatory bowel disease. J. Clin. Gastroenterol. 47, 212–221 (2013).
Zallot, C. & Peyrin-Biroulet, L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr. Gastroenterol. Rep. 15, 315 (2013).
Sandborn, W. J. The future of inflammatory bowel disease therapy: where do we go from here? Dig. Dis. 30, 140–144 (2012).
Hanauer, S. B. Medical management of Crohn's disease: treatment algorithms 2009. Dig. Dis. 27, 536–541 (2009).
Ruemmele, F. M. Pediatric inflammatory bowel diseases: coming of age. Curr. Opin. Gastroenterol. 26, 332–336 (2010).
Quiros, J. A. et al. Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. J. Pediatr. Gastroenterol. Nutr. 49, 571–579 (2009).
Heyman, M. B., Kierkus, J., Spenard, J., Shbaklo, H. & Giquere, M. Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. Inflamm. Bowel Dis. 16, 1931–1939 (2010).
Ferry, G. D. et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J. Pediatr. Gastroenterol. Nutr. 17, 32–38 (1993).
Cezard, J. P. et al. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol. Clin. Biol. 33, 31–40 (2009).
Feagan, B. G. & Macdonald, J. K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews, Issue 10. Art. No.: CD000543. http://dx.doi.org/10.1002/14651858.CD000543.pub3.
Turner, D. et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J. Pediatr. Gastroenterol. Nutr. 55, 340–361 (2012).
Sauer, C. G. & Kugathasan, S. Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Gastroenterol. Clin. North Am. 38, 611–628 (2009).
Sherlock, M. E. & Griffiths, A. M. Medical therapy for pediatric inflammatory bowel disease. Curr. Gastroenterol. Rep. 14, 166–173 (2012).
Hyams, J. S. Risk/benefit strategies must be employed in the management of pediatric Crohn's disease. Dig. Dis. 27, 291–296 (2009).
Seidman, E., Lohoues, M., Turgeon, J., Bouthillier, L. & Morin, C. Elemental diet versus prednisolone as initial therapy in Crohn's disease: early and long term results. Gastroenterology 100, A250 (1991).
Seidman, E., Griffiths, A., Jones, A. & Issenman, R. Semi-elemental (SE) diet versus prednisolone in pediatric Crohn's disease. Gastroenterology 104, A778 (1993).
Thomas, A., Taylor, F. & Miller, V. Dietary intake and nutritional treatment in childhood Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 17, 75 (1993).
Ruuska, T., Savilahti, E., Mäki, M., Ormala, T. & Visakorpi, J. K. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. J. Pediatr. Gastroenterol. Nutr. 19, 175–180 (1994).
Sanderson, I., Udeen, S., Davies, P., Savage, M. & Walker-Smith, J. Remission induced by an elemental diet in small bowel Crohn's disease. Arch. Dis. Child. 62, 123–127 (1987).
Borrelli, O. et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin. Gastroenterol. Hepatol. 4, 744–753 (2006).
Akobeng, A. K. & Thomas, A. G. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD005984. http://dx.doi.org/10.1002/14651858.CD005984.pub2.
Heuschkel, R. B., Menache, C. C., Megerian, J. T. & Baird, A. E. Enteral nutrition and corticosteroids in the treatment of acute inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 26, 310–314 (1998).
Zachos, M., Tondeur, M. & Griffiths, A. M. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.:CD000542. http://dx.doi.org/10.1002/14651858.CD000542.pub2.
Fell, J. M. et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment. Pharmacol. Ther. 14, 281–289 (2000).
Cameron, F. L. et al. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease. Aliment. Pharmacol. Ther. 37, 622–629 (2013).
Lucendo, A. J. & De Rezende, L. C. Importance of nutrition in inflammatory bowel disease. World J. Gastroenterol. 15, 2081 (2009).
Leach, S., Mitchell, H., Eng, W., Zhang, L. & Day, A. S. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. Aliment. Pharmacol. Ther. 28, 724–733 (2008).
Alhagamhmad, M. H., Day, A. S., Lemberg, D. A. & Leach, S. T. An update of the role of nutritional therapy in the management of Crohn's disease. J. Gastroenterol. 47, 872–882 (2012).
Bannerjee, K. et al. Anti-inflammatory and growth stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J. Pediatr. Gastroenterol. Nutr. 38, 270 (2004).
Modigliani, R. et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease: evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98, 811–818 (1990).
Berni Canani, R. et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig. Liver Dis. 38, 381–387 (2006).
Beattie, R. M., Nicholls, S. W., Domizio, P., Williams, C. B & Walker-Smith, J. A. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 22, 373–379 (1996).
Otley, A. et al. Budesonide use in pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 55, 200–204 (2012).
Berkelhammer, C., Trabolsi, M., Andrejic, J. & Yasmeen, T. Severe adrenal insufficiency complicating budesonide therapy for Crohn's disease. Inflamm. Bowel Dis. 17, 1053–1054 (2011).
Biancone, L. et al. Beclometasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double blind study. Dig. Liver Dis. 39, 329–337 (2007).
Romano, C. et al. Oral Beclomethasone dipropionate in pediatric active ulcerative colitis a comparison trial with mesalazine. J. Pediatr. Gastroenterol. Nutr. 50, 385–389 (2010).
Markowitz, J., Grancher, K., Kohn, N., Lesser, M. & Daum, F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119, 895–902 (2000).
Markowitz, J., Grancher, K., Kohn, N. & Daum, F. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990–2000. Am. J. Gastroenterol. 97, 928–932 (2002).
Jaspers, G. J. et al. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm. Bowel Dis. 12, 831–836 (2006).
Riello, L. et al. Tolerance and efficacy of azathioprine in pediatric Crohn's disease. Inflamm. Bowel Dis. 17, 2138–2143 (2011).
Candy, S. et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37, 674–678 (1995).
Sans, M. et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients [abstract]. Gastroenterology 144 (Suppl. 1), S109 (2011).
Punati, J. et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm. Bowel Dis. 14, 949–954 (2008).
Tajiri, H. et al. Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease. Digestion 77, 150–154 (2008).
Weiss, B. et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J. Pediatr. Gastroenterol. Nutr. 48, 526–530 (2009).
Feagan, B. G. et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N. Engl. J. Med. 332, 292–297 (1995).
Aloi, M. et al. Methotrexate in paediatric ulcerative colitis: a retrospective survey at a single tertiary referral centre. Aliment. Pharmacol. Ther. 32, 1017–1022 (2010).
Mañosa, M. et al. Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. J. Crohn's Colitis 5, 397–401 (2011).
Beaugerie, L. Immunosuppression-related lymphomas and cancers in IBD: how can they be prevented? Dig. Dis. 30, 415–419 (2012).
Hyams, J. et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132, 863–873 (2007).
Hyams, J. et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr. Med. Res. Opin. 27, 651–662 (2011).
De Bie, C. I. et al. The duration of effect of Infliximab maintenance treatment in pediatric Crohn's disease is limited. Aliment. Pharmacol. Ther. 33, 243–250 (2011).
Hyams, J. S. et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm. Bowel Dis. 15, 816–822 (2009).
Crombè, V. et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: A population-based study. Inflamm. Bowel Dis. 17, 2144–2152 (2011).
Assa, A. et al. Long-term outcome of tumor necrosis factor α antagonist's treatment in pediatric Crohn's disease. J. Crohn's Colitis 7, 369–376 (2013).
Schnitzler, F. et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm. Bowel Dis. 15, 1295–1301 (2009).
Rutgeerts, P. et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest. Endosc. 63, 433–442 (2006).
Borrelli, O. et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig. Liver Dis. 36, 342–347 (2004).
Kierkus, J. et al. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease. Eur. J. Gastroenterol. Hepatol. 24, 495–500 (2012).
Noe, J. D. & Pfefferkorn, M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm. Bowel Dis. 14, 1683–1687 (2008).
Viola, F. et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am. J. Gastroenterol. 104, 2566–2571 (2009).
Rosh, J. R. et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am. J. Gastroenterol. 104, 3042–3049 (2009).
Russell, R. K. et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment. Pharmacol. Ther. 33, 946–953 (2011).
Hyams J. S. et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 143, 365–374 (2012).
Hyams, J. S. et al. Natalizumab therapy for moderate to severe Crohn's disease in adolescents. J. Pediatr. Gastroenterol. Nutr. 44, 185–191 (2007).
D'Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660–667 (2008).
Kugathasan, S. et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am. J. Gastroenterol. 95, 3189–3194 (2000).
Lionetti, P. et al. Response to infliximab is related to disease duration in pediatric Crohn's disease. Aliment. Pharmacol. Ther. 18, 425–431 (2003).
Kim, M. J., Lee, J. S., Lee, J. H., Kim, J. Y. & Choe, Y. H. Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies. Acta Paediatr. 100, 451–455 (2011).
Lee, J. S. et al. Efficacy of early treatment with infliximab in pediatric Crohn's disease. World J. Gastroenterol. 16, 1776–1781 (2010).
Fasci Spurio, F., Aratari, A., Margagnoni, G., Doddato, M. T. & Papi, C. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid? J. Gastrointestin. Liver Dis. 21, 67–73 (2012).
Zallot, C. & Peyrin-Biroulet, L. Clinical risk factors for complicated disease: how reliable are they? Dig. Dis. 30 (Suppl. 3), 67–72 (2012).
Romberg-Camps, M. J. et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am. J. Gastroenterol. 104, 371–383 (2009).
Laharie, D. et al. Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol. Clin. Biol. 29, 145–149 (2005).
Beaugerie, L., Seksik, P., Nion-Larmurier, I., Gendre, J. P & Cosnes, J. Predictors of Crohn's disease. Gastroenterology 130, 650–656 (2006).
Mackey, A. C., Green, L., Leptak, C. & Avigan, M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J. Pediatr. Gastroenterol. Nutr. 48, 386–388 (2009).
Rosh, J. R., Gross, T., Mamula, P., Griffiths, A. & Hyams, J. Hepatosplenic T-cell lymphona in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm. Bowel Dis. 13, 1024–1030 (2007).
Cucchiara, S. et al. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J. Pediatr. Gastroenterol. Nutr. 48, 257–267 (2009).
Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383–1395 (2010).
Louis, E. et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142, 63–70 (2012).
Baert, F. et al. Influence of Immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601–608 (2003).
Farrell, R. J. et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124, 917–942 (2003).
Hanauer, S. B. et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2, 542–553 (2004).
Van Assche, G. et al. Withdrawal of immunosuppresion in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134, 1861–1868 (2008).
Cassinotti, A., Ardizzone, S. & Porro, G. B. Adalimumab for the treatment of Crohn's disease. Biologic. Targets Ther. 2, 763–777 (2008).
Sandborn, W. J. et al. Adalimumab for maintenance treatment of Crohn's disease: results of the Classic II trial. Gut 56, 1232–1239 (2007).
Cassinotti, A. & Travis, S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm. Bowel Dis. 15, 1264–1275 (2009).
Ardizzone, S., Cassinotti, A. & de Franchis, R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opin. Emerg. Drugs 17, 449–467 (2012).
Reinisch, W. et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J. Crohn's Colitis 6, 248–258 (2012).
Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462–2476 (2005).
Hyams, J. et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 10, 391–399 (2012).
Hyams, J. S. et al. Outcome following infliximab therapy in children with ulcerative colitis. Am. J. Gastroenterol. 105, 1430–1436 (2010).
Mamula, P., Markowitz, J. E., Cohen, L. J., von Allmen, D. & Baldassano, R. N. Infliximab in pediatric ulcerative colitis: two-year follow-up. J. Pediatr. Gastroenterol. Nutr. 38, 298–301 (2004).
Russell, G. H. & Katz, A. J. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 39, 166–170 (2004).
Eidelwein, A. P., Cuffari, C., Abadom, V. & Oliva-Hemker, M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis. 11, 213–218 (2005).
Fanjiang, G., Russell, G. H. & Katz, A. J. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 44, 312–317 (2007).
Cucchiara, S. et al. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig. Liver Dis. 40, S260–S264 (2008).
McGinnis, J. K. & Murray, K. F. Infliximab for ulcerative colitis in children and adolescents. J. Clin. Gastroenterol. 42, 875–879 (2008).
Nattiv, R., Wojcicki, J. M., Garnett, E. A., Gupta, N. & Heyman, M. B. High-dose infliximab for treatment of pediatric ulcerative colitis: a survey of clinical practice. World J. Gastroenterol. 18, 1229–1234 (2012).
Travis, S. P. L. et al. European evidence-based consensus on the management of ulcerative colitis: current management. J. Crohn's Colitis 2, 24–62 (2008).
Dinesen, L. et al. The pattern and outcome of acute severe colitis. J. Crohn's Colitis 4, 431–437 (2010).
Turner, D., Walsh, C. M., Steinhart, A. H. & Griffiths, A. M. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin. Gastroenterol. Hepatol. 5, 103–110 (2007).
Turner, D. et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am. J. Gastroenterol. 106, 574–588 (2011).
Turner, D. et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 133, 423–432 (2007).
Turner, D. et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 57, 331–338 (2008).
Turner, D. & Griffiths, A. M. Acute severe ulcerative colitis in children: a systematic review. Inflamm. Bowel Dis. 17, 440–449 (2011).
Laharie, D. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomized controlled trial. Lancet 380, 1909–1915 (2012).
Chang, K. H., Burke, J. P. & Coffey, J. C. Infliximab versus ciclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int. J. Colorectal Dis. 28, 287–293 (2013).
Hart, A. L. & Ng, S. C. Review article: the optimal medical management of acute severe ulcerative colitis. Aliment. Pharmacol. Ther. 32, 615–627 (2010).
Chaparro, M. et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment. Pharmacol. Ther. 35, 275–283 (2012).
Maser, E. A. et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin. Gastroenterol. Hepatol. 6, 112–116 (2008).
Manosa, M. et al. Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion 80, 30–35 (2009).
Treem, W. R., Davis, P. M. & Hyams, J. S. Cyclosporine treatment of severe ulcerative colitis in children. J. Pediatr. 119, 994–997 (1991).
Benkov, K. J., Rosh, J. R., Schwersenz, A. H., Janowitz, H. D. & LeLeiko, N. S. Cyclosporine as an alternative to surgery in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 19, 290–294 (1994).
Treem, W. R., Cohen, J., Davis, P. M., Justinich, C. J. & Hyams, J. S. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis. Colon Rectum 38, 474–479 (1995).
Barabino, A. et al. The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience. Aliment. Pharmacol. Ther. 16, 1503–1507 (2002).
Castro, M. et al. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch. Surg. 392, 161–164 (2007).
Bousvaros, A. et al. Oral tacrolimus treatment of severe colitis in children. J. Pediatr. 137, 794–799 (2000).
Ziring, D. A. et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J. Pediatr. Gastroenterol. Nutr. 45, 306–311 (2007).
Romano, C., Comito, D., Famiani, A. & Fries, W. Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis. Aliment. Pharmacol. Ther. 31, 676–677 (2010).
Bradley, G. M. & Oliva-Hemker, M. Pediatric ulcerative colitis: current treatment approaches including role of infliximab. Biologics 6, 125–134 (2012).
Monteleone, G., Pallone, F. & MacDonald, T. T. Emerging immunological targets in inflammatory bowel disease. Curr. Opin. Pharmacol. 11, 640–645 (2011).
Scharl, M. & Rogler, G. Inflammatory bowel disease pathogenesis: what is new? Curr. Opin. Gastroenterol. 28, 301–309 (2012).
Danese, S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61, 918–932 (2012).
Toussirot, E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory disease. Inflamm. Allergy Drug Targets 11, 159–168 (2012).
Sandborn, W. J. et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367, 1519–1528 (2012).
Sandborn, W. J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616–624 (2012).
Sandborn, W. J. et al. A phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis: PURSUIT SC. Gastroenterology 142 (Suppl. 1), S161 (2012).
Löwenberg, M. & D'Haens, G. Novel targets for inflammatory bowel disease therapeutics. Curr. Gastroenterol. Rep. 15, 311 (2013).
Feagan, B. G. et al. Induction therapy for ulcerative colitis. Results of GEMINI I, a randomized placebo-controlled double-blind, multicenter phase 3 trial. Gastroenterology 142 (Suppl. 1), S160–S161 (2012).
Dalal, J., Gandy, K. & Domen, J. Role of mesenchymal stem cell therapy in Crohn's disease. Pediatr. Res. 71, 445–451 (2012).
Zallot, C. & Peyrin-Biroulet, L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr. Gastroenterol. Rep. 15, 315 (2013).
Plevy, S. E. & Targan, S. R. Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology 140, 1838–1846 (2011).
Rutgeerts, P. How to guide therapeutic decision in a patient-tailored approach to treatment of IBD? Dig. Dis. 30, 396–399 (2012).
Denson, L. A. How does knowledge from translational research impact our clinical care of pediatric inflammatory bowel disease patients? Curr. Gastroenterol. Rep. 14, 275–281 (2012).
Ananthakrishnan, A. N. & Xavier, R. J. How does genotype influence disease phenotype in inflammatory bowel disease? Inflamm. Bowel Dis. 19, 2021–2030 (2013).
Author information
Authors and Affiliations
Contributions
All authors contributed equally to all aspects of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Box 1
Adverse effects of systemic corticosteroids (DOC 37 kb)
Supplementary Box 2
Adverse effects of thiopurines (DOC 37 kb)
Supplementary Box 3
Adverse effects of methotrexate (DOC 37 kb)
Supplementary Box 4
Adverse effects related to biologic therapy (DOC 37 kb)
Rights and permissions
About this article
Cite this article
Aloi, M., Nuti, F., Stronati, L. et al. Advances in the medical management of paediatric IBD. Nat Rev Gastroenterol Hepatol 11, 99–108 (2014). https://doi.org/10.1038/nrgastro.2013.158
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2013.158
This article is cited by
-
Inflammatory bowel disease addressed by Caco-2 and monocyte-derived macrophages: an opportunity for an in vitro drug screening assay
In vitro models (2022)
-
Therapeutic Effects of Mesenchymal Stem Cells Derived From Bone Marrow, Umbilical Cord Blood, and Pluripotent Stem Cells in a Mouse Model of Chemically Induced Inflammatory Bowel Disease
Inflammation (2019)
-
Pediatric inflammatory bowel disease
Indian Pediatrics (2016)
-
Long-Term Safety of Immunomodulators in Pediatric Inflammatory Diseases
Pediatric Drugs (2014)